Greenwich LifeSciences (GLSI) Cash from Operations (2019 - 2026)

Greenwich LifeSciences (GLSI) has 6 years of Cash from Operations data on file, last reported at 3174657.0 in Q4 2025.

• Quarterly Cash from Operations fell 71.4% year-over-year to 3174657.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 9913453.0 (down 36.43% YoY) and the FY2025 annual result came in at 9913453.0, down 36.43% from the prior year.
• Cash from Operations eased to 3174657.0 in Q4 2025, from 2671239.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 528270.0 in Q1 2021 to a low of 3174657.0 in Q4 2025.
• A 5-year average of 1707508.65 and a median of 1817538.5 in 2023 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations plunged 268.65% — and 2023, when it gained 20.06%.
• Tracing GLSI's Cash from Operations over 5 years: stood at 2264320.0 in 2021, then gained by 4.16% to 2170061.0 in 2022, then gained by 0.73% to 2154195.0 in 2023, then grew by 14.02% to 1852206.0 in 2024, then sank by 71.4% to 3174657.0 in 2025.
• The last three Cash from Operations figures came in at 3174657.0 (Q4 2025), 2671239.0 (Q3 2025), and 2233103.0 (Q2 2025), per Business Quant data.